Strides Arcolab shares slump as investors cast doubt on asset sale report
MUMBAI (Reuters) - Strides Arcolab Ltd (STAR.NS) slumped as much as 17.4 percent in Mumbai trading on Thursday as investors cast doubt on media reports that the drug maker may sell its injectable-medicines unit Agila Specialties.
Bloomberg News and the local media said last month that Strides was in talks to sell Agila to Pfizer Inc PFE.NS. Pfizer is doing due diligence and a deal could be reached this quarter, Bloomberg said, citing sources that it did not identify.
"There is market talk the deal with Pfizer might get delayed or cancelled," said Narayan Patra, an analyst at Systematix.
A spokesman at Strides declined to comment, while officials at Pfizer could not be immediately reached.
Shares in Striders were down 11.2 percent as of 0633 GMT.
(Reporting by Abhishek Vishnoi; Writing by Rafael Nam; Editing by Ryan Woo)
- Tweet this
- Share this
- Digg this
- Wall St. finally turning on Amazon as Bezos magic fades
- Wall Street finally turning on Amazon as Bezos magic fades
- Two dead, four wounded after student opens fire at Washington state school
- Two killed, four wounded in Washington state school shooting
- WHO vaccines boss signs up as Ebola trial guinea pig
The latest Reuters poll of 20 economists taken over the past week shows Asia's third-largest economy will likely grow 5.5 percent this fiscal year and 6.4 percent the next, slightly better than 5.3 percent and 6.3 percent expected in the July poll. Full Article
Euro zone risks "relapse into recession" without structural reforms - Draghi. Full Article
Kalki Koechlin on her role as a disabled girl in “Margarita, With a Straw” Full Article